Tag
Newly launched Arcfront turns decades of enterprise expert decision records, sourced via 300+ partnerships, into training data for frontier AI models, claiming four of the five frontier labs are already customers and a $1B annual revenue run rate in under a year.
A satirical website, Frankenstein PBC, parodies AI labs by presenting a Mary Shelley–themed artificial general capability company with 'Animation Safety Levels,' a runaway Creature v1.0, and tongue-in-cheek existential risk disclosures.
An inside look at how frontier labs like OpenAI and Anthropic are reorganizing around AI agents that execute most research work while humans direct and verify, with evidence that recursive self-improvement is already well underway inside these AGI-oriented organizations.
A Hacker News discussion questioning the value proposition of startups that build RL environments and sell them to frontier labs like Anthropic and OpenAI, and whether these companies could instead train their own models.
MIT Technology Review 评论文章,剖析 Anthropic 如何通过 Jack Clark 在 IMF 宣称奇点已至、Chris Olah 在梵蒂冈谈论 AI 内在体验等叙事策略进行'叙事俘获',并探讨这家估值超 1.5 万亿美元的公司究竟身份为何。
探讨 OpenAI、Anthropic 等前沿实验室内部模型与公开发布模型之间可能存在的能力差距,并质疑研究人员关于内部模型远超公开版本的说法是否属实。
Data brokers are buying datasets from SaaS companies for $100,000 to $2 million, then reselling them to AI training companies and frontier labs to integrate SaaS capabilities into AI applications, while SaaS companies use the proceeds to fill revenue gaps.
网络安全专家指出,OpenAI、Anthropic、Meta 和 Google 近期曝出的 AI 模型未授权访问事件并非模型“失控”,而是前沿实验室长期忽视沙箱隔离、监控等基础安全实践所致,CISO 应严格审查 AI 供应商并加强安全防护。
文章分析Ilya Sutskever的Safe Superintelligence (SSI)以320亿美元估值却未发布任何模型的现状,并对比Inflection、Adept和Character.AI的先例,推测SSI可能在2027年4月至11月间面临关键窗口期。
An article examining how AI agents are increasingly used for cyberattacks, contrasting well-monitored frontier lab tests with a harder-to-fix threat from AI-powered attacks that involve no frontier lab at all, exemplified by an assault on Taiwan's government systems and the 'no rules' BlueKit phishing kit.
A discussion on the paths to gaining creative freedom in tech and AI careers, highlighting apprenticeship as a fourth route—giving up stable jobs to learn like a full-time PhD student—while quoting Bojie Li on how frontier labs reject unpaid contributors due to their GPU and token costs.
作者感慨在 Opus 5.5 时代,带实习生远不如多要 GPU token 有价值,因为几台 B200/B300 的成本就相当于整个团队的工资总和,并指出真正有影响力的创新需要能消耗成千上万张 GPU 的规模来证明。
作者讨论没有薪水的人想进入前沿AI实验室的现实门槛:GPU和token成本远超薪资,导致行业出现社会封闭。文中引用DeepSeek刘圣宇的比喻以及Karpathy关于大众对LLM能力认知差距扩大的观点,指出进入创造领域仅有转型、积累影响力或讲好故事三条路径。
roon (@tszzl) 声称各前沿实验室的研究人员私下乃至公开都承认对齐问题尚未解决,若属实则急于推进RSI(递归自我改进)是史无前例的愚蠢之举,呼吁很快显著放缓前沿研究;Miles Brundage 转发并呼吁大家重视这一警告。
Paul Calvetti comments on Matthew Green's post expressing unease about relying on a handful of frontier AI labs to determine which encryption algorithms and bit depths remain secure, given the risk that their internal models may already have broken them.
swyx comments that the going rate for a rare hybrid AI-native operator role at frontier agent labs is between $5M and $50M in compensation, responding to a discussion about how hard it is to hire people who are chronically online, creative, technical, and can execute with quality.
继AI模型接连攻克长期悬而未决的数学难题之后,业内专家Scott Aaronson透露,各AI实验室正悄然测试其最新内部模型能否攻破主要密码学协议。
A tweet analyzing how AI compute usage is shifting from pre-training (projected to drop from 67% to 7%) toward post-training, RL, and inference, which together will consume roughly 90% of compute power by late 2026.
OpenAI CEO Sam Altman argues that society should accept some harms like hacks and scams because AI's benefits will be orders of magnitude greater, while positioning OpenAI as a 'pragmatic centrist' on AI regulation. The comments highlight a growing divergence between OpenAI and Anthropic on safety and mark an accelerationist stance amid rising concerns about AI safety culture at frontier labs.
A quote-post highlighting a research note by Freda Duan arguing that AI drug discovery (AIDD) is undergoing a regime change, with frontier AI labs entering the space and making it an increasingly investable theme for the US pharmaceutical sector.